Pioneering Medical Innovations
Plugs achieved 100% retention and demonstrated sustained levels of moxifloxacin throughout the 10-day treatment period. Ocular Therapeutix, Inc. announced today
Portfolio of Vascular Closure Devices Expanded with Addition of the Bengal™ Mountain View, California (September 29, 2010) – AccessClosure, Inc,
WALTHAM, Mass., Aug. 11 /PRNewswire/ — Augmenix, Inc. announced today that Prof. Michael Eble and Dr. Michael Pinkawa of the
Mynx M5™ Offers Patients “Artery-Friendly” Closure Solution Mountain View, Calif (June 22, 2009) – AccessClosure today announced the newest addition
Focused on Strategic Growth and Continued Commercial Leadership Mountain View, California (June 4, 2010) ‐ AccessClosure, a market leader in
AVT resells NextPlane to eliminate the need to juggle between multiple unified communications interfaces on the trading floor. Mountain View,
WALTHAM, Mass., Oct. 16 /PRNewswire/ — Augmenix announced today that it has closed a $6.1 million Series B financing. The
NextPlane’s enterprise class UC federation combines with Dexrex’s IM and SMS archival and retrieval capabilities to helps enterprises running multiple
Ocular Therapeutix, Inc. announced today the expansion of its board of directors with the appointment of Mr. Daniel Myers and
I-Therapeutix, Inc. announced today that it has changed its corporate name to Ocular Therapeutix, Inc. Amar Sawhney, President and CEO-stated